Co-enrolment

Aspirin is being given following (or alongside) standard therapy, rather than replacing any part of current treatment. By including individuals who have already taken part in other treatment trials, we will be able to assess how well aspirin works when given in addition to both current and potentially future standard treatments.

Individuals who are participating in the trials below may also enter the Add-Aspirin trial (providing they are otherwise eligible). If you would like to register an individual who has taken part in another trial, which is not listed here, please contact the Add-Aspirin trial team (details above) to discuss this.

More information about the appropriate timing of Add-Aspirin registration relative to other treatments is available in the section below (Timing of trial entry within each cohort).

Please remember to complete the Co-enrolment CRF for any patients who register in Add-Aspirin and are co-enrolled in one of the below trials, except where indicated that one is not required, e.g. because it is an observational/sample collection/non-interventional study.

Achilles tendon pain management (ATM): Co-enrolment CRF NOT required 
ARB: Co-enrolment CRF required
Bridging the Age Gap
Cardiac CARE (ISRCTN24439460): Co-enrolment CRF required
CAVA: Co-enrolment CRF NOT required
C-GALL
For any patient undergoing surgery (whether as part of the C-GALL trial or otherwise) a break in Add-Aspirin trial treatment of up to 3 months is acceptable, if deemed appropriate by the treating clinician (and is preferable to stopping treatment altogether). If regular NSAID use is prescribed (for example, as part of medical management in the C-GALL trial), the patient would need to stop Add-Aspirin trial treatment – please see section 5.11 of the protocol (v5.0) for full guidance regarding use of other medications
Chemo-NEAR: Co-enrolment CRF NOT required
ECLIPSE (2016-004424-38)
EFFECT: Co-enrolment CRF required
EndoPREDICT: Co-enrolment CRF required
EPHOS-B (ISRCTN15004993): Co-enrolment CRF required
E-RAPID: Co-enrolment CRF NOT required
eSMART: Co-enrolment CRF required
Patients should be approached for eSMART first. They should only be approached for Add-Aspirin once they have been randomised in eSMART

EUROPAC: Co-enrolment CRF NOT required
FAST-Forward (ISRCTN19906132): Co-enrolment CRF required
HORIZONS: Co-enrolment CRF NOT required
IBIS-II Prevention (ISRCTN37546358): Co-enrolment CRF required
IMPORT-HIGH (ISRCTN47437448): Co-enrolment CRF required
MITOCHONDRIAL DNA IN OXALIPLATIN INDUCED NEUROPATHY: Co-enrolment CRF NOT required 
OPPORTUNE (ISRCTN26131497): Co-enrolment CRF required
OPTIMA (ISRCTN42400492): Co-enrolment CRF required
ORANGE II (NCT01441856): Co-enrolment CRF NOT required
PALLAS (NCT02513394): Co-enrolment CRF required
PALLET (ISRCTN31243262): Co-enrolment CRF required
PARTNER (2015-002811-13): Co-enrolment CRF required
Please note the PARTNER trial must be notified when patients are co-enrolled to Add-Aspirin
Persephone (ISRCTN52968807): Co-enrolment CRF required

PIONEER (2016-003752-79): Co-enrolment CRF required

PIVOTALBoost
POBRAD-M: Co-enrolment CRF NOT required
POETIC-2 Feasibility: Co-enrolment CRF required
POSNOC (ISRCTN54765244): Co-enrolment CRF required
PQIP: Co-enrolment CRF NOT required

PRINCIPLE (hydroxycholoroquine and azithromycin arms): Co-enrolment CRF required​
PROACT (NCT03265574): Co-enrolment CRF required 
PROACT End of Study visit must be completed with confirmation that blood samples were processed successfully. Patients should not commence the aspirin run-in before this visit has taken place, but can be consented and registered to Add-Aspirin
PROSPER: Co-enrolment CRF NOT required
RIO (ISRCTN92154110): Co-enrolment CRF required
ROSCO (ISRCTN00430739): Co-enrolment CRF required
STAKT: Co-enrolment CRF required
STAKT patients can enter Add-Aspirin provided they have completed their 30 day post-treatment visit (visit 5)

TACT: Co-enrolment CRF NOT required
TARGIT-B:
 Co-enrolment CRF required
Thrombin Inhibition Preoperatively in Early Breast Cancer (TIP): Co-enrolment CRF required
USG PECS vs LIA for breast surgery: Co-enrolment CRF required

Achilles tendon pain management (ATM): Co-enrolment CRF NOT required 
ALLEGRO (ISRCTN52352431): Co-enrolment CRF required  
ARISTOTLE (ISRCTN9351447): Co-enrolment CRF required  
CAVA: Co-enrolment CRF NOT required  
C-GALL: Co-enrolment CRF required    
For any patient undergoing surgery (whether as part of the C-GALL trial or otherwise) a break in Add-Aspirin trial treatment of up to 3 months is acceptable, if deemed appropriate by the treating clinician (and is preferable to stopping treatment altogether)
If regular NSAID use is prescribed (for example, as part of medical management in the C-GALL trial), the patient would need to stop Add-Aspirin trial treatment – please see section 5.11 of the protocol (v5.0) for full guidance regarding use of other medications
CHALLENGE-UK
EMT2: Co-enrolment CRF required 
E-RAPID: Co-enrolment CRF NOT required 
eSMART: Co-enrolment CRF required  
Patients should be approached for eSMART first. they should only be approached for Add-Aspirin once they have been randomised in eSMART

EUROPAC: Co-enrolment CRF NOT required
FLOELA: Co-enrolment CRF required 
FOCCUS: Co-enrolment CRF NOT required   
FOxTROT (ISRCTN87163246): Co-enrolment CRF required  
GAMMA-CORE
HART (ISRCTN25616490): Co-enrolment CRF required 
IMPRESS: Co-enrolment CRF NOT required 
InTACT: Co-enrolment CRF required  
LaCeS: Co-enrolment CRF required

MERCURY 2 
NeoART: Co-enrolment CRF required
ORANGE II (NCT01441856): Co-enrolment CRF NOT required 
PQIP: Co-enrolment CRF NOT required 
PREPARE-ABC: Co-enrolment CRF required 
PREVENTT: Co-enrolment CRF required 
PRINCIPLE (hydroxycholoroquine and azithromycin arms): Co-enrolment CRF required

PRISM: Co-enrolment CRF NOT required

ROSSINI 2: Co-enrolment CRF required
SCOVID (13/SS/0248): Co-enrolment CRF required    
SERENADE: Co-enrolment CRF NOT required    
TRACC: Co-enrolment CRF required 
TRIGGER (ISRCTN2015-003009-40): Co-enrolment CRF required
VERDDICT: Co-enrolment CRF NOT required 

Achilles tendon pain management (ATM): Co-enrolment CRF NOT required  
CaNCaP03 (NCT02324998): Co-enrolment CRF required
CAVA: Co-enrolment CRF NOT required  
C-GALL: Co-enrolment CRF required 
For any patient undergoing surgery (whether as part of the C-GALL trial or otherwise) a break in Add-Aspirin trial treatment of up to 3 months is acceptable, if deemed appropriate by the treating clinician (and is preferable to stopping treatment altogether). If regular NSAID use is prescribed (for example, as part of medical management in the C-GALL trial), the patient would need to stop Add-Aspirin trial treatment – please see section 5.11 of the protocol (v5.0) for full guidance regarding use of other medications.
Clarity-Pro: Co-enrolment CRF NOT required 
DELINEATE: Co-enrolment CRF required 
ExPEC: Co-enrolment CRF NOT required

EUROPAC: Co-enrolment CRF NOT required
METAL: Co-enrolment CRF required 
ORANGE II (NCT01441856): Co-enrolment CRF NOT required  
PIVOTALBoost: Co-enrolment CRF required 
PQIP: Co-enrolment CRF NOT required
PRINCIPLE (hydroxycholoroquine and azithromycin arms): Co-enrolment CRF required

ProSpare II: Co-enrolment CRF NOT required
ProtecT: Co-enrolment CRF required 
RADICALS-RT (ISRCTN40814031): Co-enrolment CRF required
RADICALS-RT patients randomised into either arm of the trial (immediate or salvage post-operative radiotherapy) should only register in Add-Aspirin once radiotherapy is complete
TrueNTH: Co-enrolment CRF NOT required 
UKGPCS: Co-enrolment CRF NOT required 
VoxTox: Co-enrolment CRF NOT required

Achilles tendon pain management (ATM): Co-enrolment CRF NOT required  
BOSS: Co-enrolment CRF NOT required  
CAVA: Co-enrolment CRF NOT required  
C-GALL: Co-enrolment CRF required  
For any patient undergoing surgery (whether as part of the C-GALL trial or otherwise) a break in Add-Aspirin trial treatment of up to 3 months is acceptable, if deemed appropriate by the treating clinician (and is preferable to stopping treatment altogether). If regular NSAID use is prescribed (for example, as part of medical management in the C-GALL trial), the patient would need to stop Add-Aspirin trial treatment – please see section 5.11 of the protocol (v5.0) for full guidance regarding use of other medications.   
CYTOFLOC (NCT03529669): Co-enrolment CRF required

EUROPAC: Co-enrolment CRF NOT required
Neo-AEGIS: Co-enrolment CRF required
OPTIMISE II: Co-enrolment CRF required 
ORANGE II (NCT01441856): Co-enrolment CRF NOT required
PQIPCo-enrolment CRF NOT required 
PRE-EMPT (NCT03626610): Co-enrolment CRF required   
Prehabilitation in patients with oEsophgeal Malignancies undergoing Peri-operative Treatment 

PRINCIPLE (hydroxycholoroquine and azithromycin arms): Co-enrolment CRF required
PURASTAT: Co-enrolment CRF required  
ROMIO (ISRCTN59036820): Co-enrolment CRF required 
RTL Advanced Study: Co-enrolment CRF NOT required 
SCOPE2: Co-enrolment CRF required 
ST03 (ISRCTN46020948): Co-enrolment CRF required   
STAT-ROC (ISRCTN00131824): Co-enrolment CRF required 

Contact Details

If you are an individual who is interested in taking part in Add-Aspirin, please talk to your doctor who will be able to consider whether you are suitable for the trial.

For healthcare professionals

Please log into the members area for Add-Aspirin contact details.

Register Interest

For healthcare professionals

If your centre would like to recruit participants to Add-Aspirin, contact us:
mrcctu.add-aspirin@ucl.ac.uk

Register a participant

To RANDOMISE a participant in the UK please call +44 (0)20 7670 4777

To RANDOMISE a participant from Republic of Ireland or India only, please use the 'Register a participant' link above to randomise online. Please make sure to press 'Randomise' once logged in to the server.

Unblind a participant in the UK

Unblind a participant in the RoI

Unblind a participant in India